Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Weight loss, risks of GLP-1
The FDA is about to make weight-loss drugs a lot harder to get
Lots of people are on cheaper compounded weight-loss drugs that mimic brands like Ozempic, Wegovy, and Zepbound. They're about to lose access.
The Health Risks and Benefits of Weight-Loss Drugs
T he newest weight-loss drugs, Wegovy and Zepbound, are incredibly popular. But doctors are still learning about all of the ways they affect the body—both helpful and harmful—beyond reducing weight. In report published in Nature Medicine,
Massive study looks at benefits, risks of GLP-1 weight-loss drugs
As demand for weight-loss injections sold under brand names such as Ozempic and Wegovy continues to soar, a study has uncovered neurological and behavioral health benefits amid risks for pancreatitis and kidney disease.
7h
Diabetes startup Virta Health is now prescribing Ozempic for weight loss in a push toward profitability and IPO
The diabetes startup is prescribing GLP-1 drugs for weight loss to help employers manage costs. Its CEO says it's nearing ...
phillyvoice.com
1d
Ozempic and Wegovy are helping many Americans lose weight, but they also may have other beneficial uses
News research shows GLP-1 medications may help treat a wide range of conditions, from addiction and dementia to heart disease ...
2d
on MSN
Experts with Mercy discuss differences between bariatric surgery and drugs for weight loss
When it comes to medically assisted weight loss, there’s two main schools of thought: either weight loss drugs, like the ...
1d
on MSN
A woman regained weight after she stopped taking semaglutide. Now she works two jobs to afford it.
A woman who lost 64 pounds on a compounded form of the weight loss drug semaglutide, marketed as Wegovy and Ozempic, started ...
2d
Largest-ever Ozempic and GLP-1 drug study finds they lower risk of 42 health conditions, including heart attacks and Alzheimer’s disease
The study included nearly 2 million patients, making it the largest ever conducted on this group of glucagon-like peptide-1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
Ozempic
Medicare
Wegovy
Novo Nordisk
FDA
Feedback